Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short-term Investments (2016 - 2025)

Cytokinetics (CYTK) has disclosed Short-term Investments for 16 consecutive years, with $759.7 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments changed N/A to $759.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $759.7 million through Dec 2025, changed N/A year-over-year, with the annual reading at $759.7 million for FY2025, N/A changed from the prior year.
  • Short-term Investments for Q4 2025 was $759.7 million at Cytokinetics, up from $737.1 million in the prior quarter.
  • The five-year high for Short-term Investments was $964.8 million in Q3 2024, with the low at $313.1 million in Q2 2021.
  • Average Short-term Investments over 5 years is $599.0 million, with a median of $501.8 million recorded in 2023.
  • The sharpest move saw Short-term Investments skyrocketed 122.89% in 2021, then crashed 42.27% in 2023.
  • Over 5 years, Short-term Investments stood at $359.0 million in 2021, then skyrocketed by 99.74% to $717.0 million in 2022, then crashed by 30.01% to $501.8 million in 2023, then skyrocketed by 92.27% to $964.8 million in 2024, then decreased by 21.26% to $759.7 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $759.7 million, $737.1 million, and $783.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.